top of page

VKTX

Viking Therapeutics

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$184.9M

Burn Rate (Qtr)

$10.5M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Create Free Account Now

Loading Catalysts...

search in progress

Pipeline powered by

VKTX

BPIQ_Logo_RGB-01.jpg

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Recent Posts

See what the community is saying - click to see full post.

VKTX VK2735 New Data at Obesity Week 2024

5 Stocks Likely To Move Big On An Early-Stage Readout

5 Stocks Likely To Move Big On An Early-Stage Readout

VKTX Soars 28% on Q2 Call: Key Takeaways, Pipeline Updates, and What's Next

VKTX Soars 28% on Q2 Call: Key Takeaways, Pipeline Updates, and What's Next

Oral GLP-1 Obesity Market: Assessing Roche CT-996 Ph1 Data

bottom of page